BioSpace News Archive

Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today that as a continuation of the Brand Building of its CaverStemTM technology

GAAP diluted EPS of $0.79 declined by 9.2% over prior-year GAAP diluted EPS

Before 1968, hemolytic disease of the newborn (HDFN) claimed the lives of 10,000 infants per year in the U.S. alone; since then, this easily preventable condition has virtually disappeared from the United States, Canada, Western Europe, and Australia thanks to the discovery and regulatory approval of Rh immunoglobulin (RhIG), also called “anti-D therapy” for human use in preventing Rh sensitization (i.e., Rh disease). Rh disease can lead to HDFN.

The Blu Genes Foundation has donated $1.4 million to University of Massachusetts Medical School for the advancement of a Phase I/II clinical trial for the genetic disorder known as Tay-Sachs.

Announced launch of a Phase1b/2 trial for AST-008, Exicure’s TLR9 agonist drug candidate designed for immuno-oncology applications.

AmorChem was built through the vision and leadership of its two founders, Elizabeth Douville and Inès Holzbaur, making it one of the rare venture capital funds led by two women.

Third Quarter 2018 GAAP Revenue of $160.8 million, up 10% year over year

Pyramidion Technology Group, Inc. (OTC: PYTG), will exhibit select Cannabidiol-containing (CBD) products from the LeafyWell (LeafyWell.com) product lines at the Continuing Medical Education (CME) program sponsored by the University of Miami Leonard M. Miller School of Medicine.

Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer.

Biomarkers demonstrate 95% sensitivity and 97.5% specificity in diagnosing hepatocellular carcinoma